Nat. Rev. Rheumatol. doi: /nrrheum

Slides:

Advertisements

Similar presentations

1 Classification criteria for APS Clinical Criteria (Sydney 2004) Myakis et al. J Thromb Haemost 2006;4: Vascular thrombosis one or more clinical.

Advertisements

ANTIPHOSPHOLIPID SYNDROME CLINICAL MANIFESTATIONS.

Antiphospholipid Antibody Syndrome

A. Antiphospholipid antibody syndrome

Figure 4 Time course of the development of physiological changes

Figure 3 Connexins in cartilage

Figure 1 Historical evolution of the clinical classification and

Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.

Figure 10 Assessment of myocardial fibrosis

Figure 2 Representative MSI data obtained from human joints

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Figure 1 Grip strength across the lifecourse

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Factors underlying metabolic alterations in osteoarthritis

Figure 1 Induction of immune tolerance

Valvular heart disease

Figure 8 Implanted devices for the management of heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Targeted versus untargeted metabolomics approaches

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Figure 4 Antinuclear antibodies and disease activity in SLE

Figure 3 Transcriptome studies performed in the target

Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 7 Defects in apoptosis

Figure 3 Nucleic acid sensors in SLE

Figure 8 4D magnetic resonance imaging patterns

Figure 3 Strategies to achieve therapeutic inhibition of IL-1

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 Post-test probability as a function of pre-test

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Statistical approaches for the analysis of metabolomic data

Figure 3 Cell-surface markers for NP cell differentiation

Figure 6 Lack of IRF5 causes a reduction in neutrophil influx

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Decision tree integrating the assessment,

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Multi-hit model for autoimmune diseases

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Research advances in osteoarthritis management

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Treat to target, remission and low disease activity in SLE

Figure 1 Biospecimen handling pipeline

Figure 1 The current model of the pathogenesis of SLE

Figure 6 Metabolism of pterins

Figure 1 Reproductive health in patients with rheumatic diseases

Figure 1 Principles for the diagnosis and management of osteoarthritis

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Cardiol. doi: /nrcardio

Figure 9 Management of atrial fibrillation

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Nuclear-penetrating autoantibodies and synthetic lethality

Figure 1 Overall worldwide prevalence ranges for SLE

Figure 2 Phenotypes of osteoarthritis

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Clinical and histological features of the skin in dermatomyositis and conditions that mimic dermatomyositis Figure 2 | Clinical and histological.

Figure 2 The main effects of adipokines on bone remodelling in osteoarthritis Figure 2 | The main effects of adipokines on bone remodelling in osteoarthritis.

Nat. Rev. Cardiol. doi: /nrcardio

Presentation transcript:

Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.124 Figure 1 Extra-criteria clinical manifestations of antiphospholipid syndrome Figure 1 | Extra-criteria clinical manifestations of antiphospholipid syndrome. The clinical spectrum of antiphospholipid syndrome (APS) is not limited to vascular thrombosis and miscarriages, but includes additional manifestations that cannot be explained solely by a thrombophilic state. Since the disease was first defined, the clinical spectrum of APS has been extended to include many other manifestations. Thrombocytopenia, valvular heart disease (valve thickening, vegetations and regurgitation), antiphospholipid antibody-related nephropathy, livedo reticularis and skin ulcers are relatively common features of APS, but are not included in the classification criteria for the syndrome15. Sciascia, S. et al. (2017) Diagnosing antiphospholipid syndrome: ‘extra-criteria’ manifestations and technical advances Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.124